Wuxi Kaili

Kaili (Wuxi) Pharmaceutical Technology, commonly known as Kaili Pharma, is a clinical-stage biotechnology company based in Wuxi, China, specializing in the development of targeted protein degradation therapies. The company leverages its proprietary PROTAC (Proteolysis-Targeting Chimera) platform to design small molecules that recruit the body's natural ubiquitin-proteasome system to eliminate disease-causing proteins. Their lead candidate, KP-001, is a potent BTK degrader currently in Phase 1 clinical trials for the treatment of B-cell malignancies, aiming to overcome resistance seen with traditional BTK inhibitors. Kaili Pharma's pipeline also includes several pre-clinical programs targeting the androgen receptor and estrogen receptor for solid tumors. Founded by industry veterans, the company is a key player in the emerging protein degradation landscape in Asia.